Immuno-Oncology (IO) is uniquely positioned to become the fifth pillar of cancer treatment alongside surgery, radiotherapy, chemotherapy, and other targeted treatments. In order to assist our clients with navigating the burgeoning amount information arising as a result of the rapidly growing field of IO clinical research, GlobalData is offering a comprehensive analysis of both pipeline and marketed active immunity IO therapies
Scope
The PharmaFocus consists of a highly-visual slide deck that is intended to facilitate the dissemination of aggregated data and insights from analyses of over 800 IO products that are either marketed or in Phase I-III of clinical development.
Types of graphical analyses include:
Cumulative Plots
Aggregated Bubble Plots
Pie Charts
Matrix Analyses
Unique, actionable insights applicable to IO drugs in five major categories: Immune Checkpoint Modulators, Cellular Immunotherapies, Oncolytic Viruses, Peptide Vaccines, and Bispecific T-Cell Engagers are provided in this report.
Analysis of over 4000 clinical trials enrolling patients with 18 solid tumors and eight hematological cancers are included.
Key Highlights
Key Topics Covered
- Immune Checkpoint Modulators – Trends in Clinical Trial Development
- Competitive Assessment of Marketed PD-(L)1 Checkpoint Modulators
- Emergence of New Immune Checkpoint Targets
- Clinical and Commercial Opportunities for Highly Anticipated CAR Cell Therapies
- Cell Vaccines: Steady Development Stimulated by Prior IO Success
- Promising IO-IO Combinations Utilizing Oncolytic Viruses
Table of Contents
Table of Contents
1. Preface
1.1 Related Reports
1.2 Upcoming Reports
1.3 Abbreviations
2. Immuno-Oncology Product Definition and Classification
3. Recent Timeline ...
Table of Contents
1. Preface
1.1 Related Reports
1.2 Upcoming Reports
1.3 Abbreviations
2. Immuno-Oncology Product Definition and Classification
3. Recent Timeline of Immuno-Oncology Approvals
4. Immune Checkpoint Modulators – Trends in Clinical Trial Development
4.1 Clinical Trial Activity for Checkpoint Modulators Remains Essentially Driven by PD-(L)1 and CTLA-4 Targeting Agents
4.2 Academic Institutions Are Key Drivers for Early Stage Clinical Research, but Patient Recruitment is Highly Dependent on Companies
4.3 Geographic Locations of Trials Assessing Immune Checkpoint Modulators
5. Competitive Assessment of Marketed PD-(L)1 Checkpoint Modulators
5.1 Clinical Positioning of Marketed PD-(L)1 Inhibitors
5.2 Commercial Attributes of Marketed PD-(L)1 Checkpoint Modulators
5.3 Dynamic of Clinical Development for Marketed PD-(L)1 Checkpoint Modulators
5.4 Clinical Development Coverage of Marketed PD-(L)1 Checkpoint Modulators in Solid Tumors and Blood Cancers
6. Emergence of New Immune Checkpoint Targets
6.1 Emergence of New Checkpoint Targets in Clinical Development
6.2 Clinical Development Coverage of Emerging Targets in Solid Tumors and Blood Cancers – Matrix Analysis
7. Cellular Immunotherapies in Clinical Development
7.1 Clinical Development of Cellular Immunotherapies
7.2 Clinical Development of Cytotoxic Cellular Immunotherapies
8. Clinical and Commercial Opportunities for Highly Anticipated CAR Cell Therapies
8.1 Development of and Opportunities for CAR Cell Therapies
8.2 Development of CAR Cell Therapies in Blood Cancers
8.3 Development of CAR Cell Therapies in Solid Tumors
9. Cell Vaccines: Steady Development Stimulated by Prior IO Success
9.1 Trends in Clinical Development of Cancer Vaccines
10. T-cell Redirecting Therapies: Comparison Between CAR Cell Therapies and Bispecific T-Cell Engager Antibodies
10.1 Development of CAR Cell Therapies and Bispecific T-Cell Engagers
11. Promising IO-IO Combinations Utilizing Oncolytic Viruses
11.1 Combination Strategies of Oncolytic Viruses with Other IO Agents Create New Clinical Opportunities
12. Appendix
12.1 Inclusion Criteria for IO Products
12.2 Exclusion Criteria for IO Products
12.3 Identification of Immuno-Oncology Products Based on Targets and Molecule Types
12.4 Data Export from the Pharma Intelligence Center
12.5 Primary Research
12.6 Bibliography
12.7 About the Authors
12.8 About GlobalData
12.9 Contact Us
12.10 Disclaimer